Text Size: a  |   a 

Roche Plans to Launch Data for 9 New Medicines in Next 3 Years; Including An MS Agent

November 5, 2015

Swiss pharmaceutical company Roche plans to launch pivotal data on nine new medicines within the next three years, looking to offset risks posed by copycat versions of older drugs.

One of the most anticipated products is the ocrelizumab medicine for MS. In October 2010, results from a study revealed a significant reduction in disease activity among patients with RRMS, as measured by brain lesions.

Aside from the MS agent, they are banking on the immune–system boosting atezolizumad to treat bladder and lung cancer, as well as ACE-910 to treat hemophilia.

Roche said it expects up to seven major results from clinical trials on new drugs or extensions for existing medicines through 2017. That would add to seven clinical study results released this year.